| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash used in investing activities | -246,695 | -167,343 |
| Proceeds from issuance of common stock, net of issuance costs | 27,217 | 17,794 |
| Net cash provided by financing activities | 27,217 | 17,794 |
| Effect of exchange rate changes on cash | 19 | 19 |
| Net decrease in cash, cash equivalents and restricted cash | -60,892 | -65,251 |
| Cash and cash equivalents at beginning of period | 328,359 | - |
| Cash and cash equivalents at end of period | 267,467 | - |
ACADIA PHARMACEUTICALS INC (ACAD)
ACADIA PHARMACEUTICALS INC (ACAD)